key: cord-0960997-abyef3db authors: Garneret, P.; Coz, E.; Martin, E.; Manuguerra, J.-C.; Brient-Litzler, E.; Enouf, V.; Gonzalez Obando, D. F.; Olivo-Marin, J.-C.; Monti, F.; Van der Werf, S.; Vanhomwegen, J.; Tabeling, P. J. title: Highly performing point-of-care molecular testing for SARS-CoV-2 with RNA extraction and isothermal amplification. date: 2020-08-04 journal: nan DOI: 10.1101/2020.08.01.20166538 sha: a047c75c0b8a5156ccb34bfbd316bf3356b791b5 doc_id: 960997 cord_uid: abyef3db In order to respond to the urgent request of massive testing, developed countries perform nucleic acid amplification tests (NAAT) of SARS-CoV-2 in centralized laboratories. Real-time RT - PCR (Reverse transcription - Polymerase Chain Reaction) is used to amplify the viral RNA and enable its detection. Although PCR is 37 years old, it is still considered, without dispute, as the gold standard. PCR is an efficient process, but the complex engineering required for automated RNA extraction and temperature cycling makes it incompatible for use in point of care settings. In the present work, by harnessing progress made in the past two decades in DNA amplification, microfluidics and membrane technologies, we succeeded to create a portable test, in which SARS-CoV-2 RNA is extracted, amplified isothermally by RT - LAMP (Loop-mediated Isothermal Amplification), and detected using intercalating dyes or highly fluorescent probes. Depending on the viral load, the detection takes between twenty minutes and one hour. Using pools of naso-pharyngal clinical samples, we estimated a sensitivity comparable to RT-qPCR (up to a Cycle threshold of 39, equivalent to <0.1 TCID50 per mL) and a 100% specificity, for other human coronaviruses and eight respiratory viruses currently circulating in Europe. We designed and fabricated an easy-to-use portable device called COVIDISC to carry out the test at the point of care. The low cost of the materials along with the absence of complex equipment paves the way towards a large dissemination of this device. The perspective of a reliable SARS-CoV-2 point of care detection, highly performing, that would deliver on-site results in less than one hour opens up a new efficient approach to manage the pandemics. performing NAATs but today, PCR (Polymerase Chain Reaction), coupled to extraction, is considered as the gold standard. The main problem of PCR is that, due to an inherent complexity, the only way to obtain high throughputs is to perform highly parallelized tests in centralized laboratories. This generates logistics issues, long delivery times, (several days in practice) and costs unaffordable for developing countries. Over the last ten years, with the advent of isothermal amplification technologies (2) , a new area of research has opened, raising hope to perform NAATs at the point of care, with portable devices much cheaper than extraction/PCR platforms and showing comparable performances. A new generation of NAATs has grown along the years, in laboratories, often coupling isothermal amplification to paper microfluidics, a field pioneered by G.Whitesides (3) (4) (5) (6) (7) (8) (9) (10) (11) (12) (13) (14) (15) (16) . Unfortunately, this second generation of testing, despite its potential, did not succeed to take off as a point of care (POC) product, for several reasons (low practicability of the devices, absence of sample preparation, in particular RNA extraction, clinical and analytical performances still to be assessed, costly surrounding equipment, competitiveness,…). Thereby, as SARS-CoV-2 started to propagate around the world, the isothermal technology was not ready to face the urgent request of global massive testing. Over these last weeks, stimulated by the crisis, isothermal commercial machines have been proposed (17). However, because of cost, throughput and performance limitations, they do not represent yet an alternative to the current extraction/RT-PCR technology. Laboratory isothermal detection of SARS-CoV-2 have been reported in the literature, but only in microtube strips (18-21). By carrying out series of improvements and optimizations over the last six years, we made a technological leap in the domain. The new generation of molecular tests we report here combines membrane extraction, RT-LAMP testing (22) and paper microfluidics. It has performances comparable to the extraction/RT-PCR method, with a potential to be used promptly for the detection of SARS-CoV-2 at the point of care. The laboratory device we used is displayed on Fig 1A. Two sheets of polypropylene (black), two centimeters in size, incorporate pretreated laser-cut disks, one (oblong form) for nucleic acid extraction, and the two others (circular disks) for the RT-LAMP reactions. The oblong disk is a commercial silicon membrane similar to those optimized for RNA extraction (23), the others are made of glass fiber (Watman). Figure 1B decomposes the workflow. The lysed sample is injected onto the extraction membrane and washed (24-25). After drying, the device is folded so as to place the oblong extraction membrane in contact withthe two reaction disks. Then RNA elution is achieved, using the rehydrationbuffer. In this process, . CC-BY-NC-ND 4.0 International license It is made available under a perpetuity. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint The copyright holder for this this version posted August 4, 2020. . the captured RNA is driven towards the reaction disk, by capillary action. On both disks, the reaction mix gets hydrated and, upon temperature rise to 65°C, reverse transcription and amplification are performed. We use real-time RT-LAMP, whose kinetics is measured by tracking the fluorescence emission of a DNA intercalating dye. -Folding of the device in such a way that the extraction membrane comes into contact with the two reaction disks. On both disk is freeze-dried the LAMP mix and primers (Covid-19 and human 18S RNA for the test and control disk respectively) permiting reverse transcription and amplification. 5 -Elution of the RNA from the capture membrane to the reaction disks, then, sealing with PCR tape 6 -Heating at 65°C. Read-out in real time with an intercalating agent (SYTO82). We now use the device of is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint The copyright holder for this this version posted August 4, 2020. . https://doi.org/10.1101/2020.08.01.20166538 doi: medRxiv preprint signal plotted on Figure 2 is the average value of the 25% brighter pixels within the reaction disk, a simple approach to take into account profiles of low Ct samples, where the reaction is confined in a subpart of the disk. This feature suggests that a classification based on the fluorescence standard deviation could also be envisaged (see SupMat 4). is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint The copyright holder for this this version posted August 4, 2020. . https://doi.org/10.1101/2020.08.01.20166538 doi: medRxiv preprint The right part of Figure 2 addresses the question of the specificity. The images show that for non-SARS-CoV-2 pathogens, fluorescence is barely visible. This is confirmed by intensity measurements, which show that the fluorescence level is indistinguishable from the background. One may conclude that the specificity of the test, based on this limited set of pathogens, is 100%. In order to transform the foldable paper system into a practical POC device , we created the "COVIDISC", shown in is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint The copyright holder for this this version posted August 4, 2020. . https://doi.org/10.1101/2020.08.01.20166538 doi: medRxiv preprint oven to maintain the temperature at 65°C and one LED and two gelatin filters to take the picture. The equipment needed for running the test is thus minimal. The results presented here have been obtained with 39 clinical samples. Although a confirmation on larger sets is desirable, our measurements indicate that, with a minimal equipment, one can extract, wash, elute, reverse-transcribe, amplify and measure the kinetics, with a sensitivity comparable to the gold standard RT-qPCR, i.e. 39 cycles (a few genome copies per reaction) and a specificity, based on the set of pathogens we used, of 100%. We also created a portable device (COVIDISC) that can be used at the point of care with minimal equipment (30). This work paves the way toward reliable point of care testing of SARS-CoV-2, both in developing and developed countries. Performing these tests at the doctor's office, at the working place or in pharmacies could allow the isolation of infected patients without delay, fastenning their quarantine,reducing logistics and costs and offering a new efficient approach to manage the pandemics. In the future, obviously, the same technology could be used for other pathogens. Lamb et al (19,28) ) Primer Sequence (5' to 3') Covid-19_F3 TCCAGATGAGGATGAAGAAGA Covid-19_B3 AGTCTGAACAACTGGTGTAAG Covid-19_FIP AGAGCAGCAGAAGTGGCACAGGTGATTGTGAAGAAGAAGAG Covid-19_BIP TCAACCTGAAGAAGAGCAAGAACTGATTGTCCTCACTGCC Covid-19_LoopF CTCATATTGAGTTGATGGCTCA Covid-19_LoopB ACAAACTGTTGGTCAACAAGAC 18S_rRNA_L3 GTTCAAAGCAGGCCCGAG 18S_rRNA_B3 CCTCCGACTTTCGTTCTTGA 18S_rRNA_FIP TGGCCTCAGTTCCGAAAACCAACCTGGATACCGCAGCTAGG 18S_rRNA_BIP GGCATTCGTATTGCGCCGCTGGCAAATGCTTTCGCTCTG 18S_rRNA_LoopF AGAACCGCGGTCCTATTCCATTATT 18S_rRNA_LoopB ATTCCTTGGACCGGCGCAAG In our device, each clinical sample is split into two reaction disks: a SARS-CoV-2 test and an internal control (human 18S ribosomal RNA) test. This internal control can help identify several types of problems: (i) too little human material in the sample; (ii) the RNA extraction step did not work; (iii) the reagents lyophilized on the device don't work anymore (e.g. due to wrong storage conditions, expired device…); (iv) the amplification did not work due to a misfunction of the heater. The result of the SARS-CoV-2 test should be rejected if the internal control test is not positive. For each data point presented in Figure 2 , we ran an internal control on the same device, with a RT-LAMP mix detecting human 18S ribosomal RNA. The histogram of these 39 data points is represented on Figure S3 . The minimal signal of all these controls (2312 a.u.) is well above the average value of the no template controls (703 a.u. ± 52 a.u, 5 replicates). (standard deviation)) (See Fig S3) . The histogram is substantially broad; it may reflect the fact that the amount of human material, and thereby that of 18S RNA, may vary from one sample to the other. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint The copyright holder for this this version posted August 4, 2020. . List of operations to be realized to perform the test on the COVIDISC Inject the lysed sample onto the extraction membrane 2 Inject the washing buffer to wash the membrane 3 Wait a few minutes for drying 4 Turn the upper disk by 90°to place the extraction membrane onto the reaction disk 5 Inject the elution buffer to elute onto the reaction risk 6 Turn the upper disk by 90° in the opposite direction 7 Cover the reaction disk with a sealing PCR film (an operation that can be suppressed by modifying the design) 8 Place the COVIDISC in an oven at 65°C for ~ 45 min -1h 9 After returning to room temperature, read the fluorescence with the naked eye or a cell phone using appropriate filters Experimental set-up to record fluorescence and signal processing . CC-BY-NC-ND 4.0 International license It is made available under a perpetuity. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint The copyright holder for this this version posted August 4, 2020. . https://doi.org/10.1101/2020.08.01.20166538 doi: medRxiv preprint In the lab we used a dedicated set-up to acquire fluorescence, based on a Leica Z16 APO macroscope, equipped with FAM and Texas red cubes, and recorded images using an EM-CCD camera from Hamamatsu. This set up acquired an image of the reaction disks placed on a 65°C plate every 10 seconds. Reaction disks were detected using active contours to automatically delineate their shape, using an image of the device taken before heating/starting the amplification. A single seed point inside each disk needs to be provided to perform each contour estimation. The Icy image analysis platform (www.icy.fr) was used to extract the data. The fluorescence signal plotted on Figure 2 is the average value of the 25% brighter pixels within the reaction disk, a simple approach to take into account profiles of high Ct (low viral load) samples, where the reaction happens and results in very bright pixels only in a subpart of the disk. We explored whether the heterogeneity of the fluorescence within the reaction disks could be used to reinforce the classification. We found out that the standard deviation (SD) of the fluorescence intensity within the reaction disk could increase the contrast between COVID-19 pools and negatives/other viruses samples ( Figure S4 ). A SD threshold can thus classify all COVID-19 pools as positive and the negatives/non-specific samples as negative. We will explore in further experiments whether this parameter could complete/replace the fluorescence intensity to better classify tests as positive or negative. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint The copyright holder for this this version posted August 4, 2020. . https://doi.org/10.1101/2020.08.01.20166538 doi: medRxiv preprint Making PCR: A Story of Biotechnology Samples used in this study were collected as part of approved ongoing surveillance conducted by the National Reference Center for Respiratory Viruses (NRC) at Institut Pasteur (WHO reference laboratory providing confirmatory testing for COVID-19). The lab investigations described in this article were carried out in accordance with French Law which does not required a review by an ethics committee for the secondary use of samples collected for healthcare purposes. However, to fulfill editorial requirements, an Ethics waiver (reference 2020/08) has been obtained by the Institut Pasteur from a French Ethics Committee (Comité de Protection des Personnes Ile de France IV, IRB#00003835).